Intravenous immunglobulin binds beta amyloid and modifies its aggregation, neurotoxicity and microglial phagocytosis in vitro.

Intravenous immunglobulin binds beta amyloid and modifies its aggregation, neurotoxicity and microglial phagocytosis in vitro.

Intravenous Immunoglobulin (IVIG) has been proposed as a potential therapeutic for Alzheimer's disease (AD) and its efficacy is currently being tested in mild-to-moderate AD. Earlier studies reported the presence of anti-amyloid beta (Aβ) antibodies in IVIG. These observations led to clinical s...

Full description

Bibliographic Details
Main Authors: Susann Cattepoel, Alexander Schaub, Miriam Ender, Annette Gaida, Alain Kropf, Ursula Guggisberg, Marc W Nolte, Louis Fabri, Paul A Adlard, David I Finkelstein, Reinhard Bolli, Sylvia M Miescher
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3656042?pdf=render

Internet

http://europepmc.org/articles/PMC3656042?pdf=render

Similar Items